Documentos de Rao-Melacini P. | REDI

Regresar

Mostrando 10 resultados de: 12

Filtros aplicados

Origen: "google"

Subtipo de publicación

Publisher

American Journal of Hypertension(1)

Diabetes, Obesity and Metabolism(1)

Journal of Clinical Endocrinology and Metabolism(1)

Área temáticas

Enfermedades(10)

Medicina y salud(6)

Farmacología y terapéutica(5)

Problemas sociales y servicios a grupos(4)

Fisiología humana(3)

Área de conocimiento

Epidemiología(5)

Medicina interna(5)

Año de Publicación

Origen

Palabras Claves

Hypertension(2)

Apolipoproteins(1)

Atrial Fibrillation(1)

Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)

Abstract: Background and Purpose The association of dyslipidemia with stroke has been inconsistent, which may

Palabras claves:

Apolipoproteins, Case-control, dyslipidemia, Lipoproteins, risk factor, stroke

Avezum A.J., Chin S.L., Czlonkowska A., Damasceno A., Dans A.L., DIaz R., Diener H.C., ElSayed A., Ferguson J., Hankey G.J., Hussain F.A., Iqbal R., Iversen H.K., Judge C., Lanas F., Langhorne P., Lisheng L., Málaga G., McQueen M.J., Mondo C.K., Nilanont Y., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’donnell M.J., Pais P., Paré G., PATRICIO LOPEZ -JARAMILLO, Peñaherrera E., Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Sniderman A., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H.

Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

Abstract: Background Stroke is a leading cause of death and disability, especially in low-income and middle-in

Palabras claves:

Agapay S., Al Hussain F., Avezum A.J., Chin S.L., Czlonkowska A., Damasceno A., Dans A.M., Dehghan M., DIaz R., Diener H.C., ElSayed A., Ferguson J., Hankey G.J., Iqbal R., Iversen H.K., Lanas F., Langhorne P., Liu L., Magazi D., Málaga G., McQueen M.J., Mondo C.K., Nilanont Y., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’Donnell M., Pais P., Paré G., PATRICIO LOPEZ -JARAMILLO, Peñaherrera E., Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H., Zhang X.

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial

Abstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 r

Palabras claves:

Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Abstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate

Palabras claves:

Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Abstract: Background: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular

Palabras claves:

Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Riesmeyer J.S., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.

Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial

Abstract: Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in

Palabras claves:

Atrial Fibrillation, atrial flutter, dulaglutide, glucagon-like peptide-1 receptor agonists, Type 2 Diabetes

Avezum A.J., Basile J.N., C. Gerstein H., Conget I., Cushman W.C., Dagenais G.R., Hoover A., Jansky P., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Sheu W.H.H., Temelkova-Kurktschiev T.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Abstract: Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people w

Palabras claves:

Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Botros F.T., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

Abstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshi

Palabras claves:

cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, stroke

Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.

Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case-Control Study

Abstract: Although low sodium intake (<2 g/day) and high potassium intake (>3.5 g/day) are proposed as public

Palabras claves:

Blood pressure, Hypertension, Intracerebral Hemorrhage, Ischemic stroke, potassium, Sodium, stroke

Al Hussain F., Avezum A.J., Chin S.L., Czlonkowska A., Damasceno A., Dans A.M., DIaz R., ElSayed A., Ferguson J., Hankey G.J., Iversen H.K., Judge C., Lanas F.T., Langhorne P., Lisheng L., Málaga G., Mondo C.K., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Smyth A., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H.

Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level

Abstract: Objective Hypertension is the most important modifiable risk factor for stroke globally. We hypothes

Palabras claves:

epidemiology, Hypertension, stroke

Alhussain F., Avezum A.J., Chin S.L., Czlonkowska A., Daliwonga M., Damasceno A., Dans A.M., DIaz R., Diener H.C., ElSayed A., Ferguson J., Hankey G.J., Iqbal R., Iversen H.K., Judge C., Lanas F.T., Langhorne P., Lisheng L., Málaga G., Mondo C.K., Nilanont Y., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’Donnell M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peñaherrera E., Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Smyth A., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H.